...
首页> 外文期刊>International journal of colorectal disease. >Evaluation of four comorbidity indices and Charlson comorbidity index adjustment for colorectal cancer patients
【24h】

Evaluation of four comorbidity indices and Charlson comorbidity index adjustment for colorectal cancer patients

机译:结直肠癌患者四种合并症指数和Charlson合并症指数调整的评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Introduction: Cancer survival is related not only to primary malignancy but also to concomitant nonmalignant diseases. The aim of this study was to investigate the prognostic capacity of four comorbidity indices [the Charlson comorbidity index (CCI), the Elixhauser method, the National Institute on Aging (NIA) and National Cancer Institute (NCI) comorbidity index, and the Adult Comorbidity Evaluation-27 (ACE-27)] for both cancer-related and all-cause mortality among colorectal cancer patients. A modified version of the CCI adapted for colorectal cancer patients was also built. Methods: The study population comprised 468 cases of colorectal cancer diagnosed between 1 January 2000 and 31 December 2010 at a community hospital. Data were prospectively collected and abstracted from patients' clinical records. Kaplan-Meier method and multivariate logistic regression models were performed for survival and risk of death analysis. Results: Only moderate or severe renal disease [hazard ratio (HR) 2.71, 95 % confidence interval (CI) 1.11-6.63] and AIDS (HR 3.27, 95 % CI 1.23-8.68) were independently associated with cancer-specific mortality, with a population attributable risk of 5.18 and 4.36 %, respectively. For each index, the highest comorbidity burden was significantly associated with poorer overall survival (NIA/NCI: HR 2.14, 95 % CI 1.14-4.01; Elixhauser: HR 1.98, 95 % CI 1.09-1.42; ACE-27: HR 1.78, 95 % CI 1.07-1.23; CCI: HR 1.68, 95 % CI 1.05-1.42) and cancer-specific survival. The modified version of the CCI resulted in a higher predictive power compared with other indices studied (cancer-specific mortality HR=2.37, 95 % CI 1.37-4.08). Conclusions: The comorbidity assessment tools provided better prognostic prevision of prospective outcome of colorectal cancer patients than single comorbid conditions.
机译:简介:癌症的生存不仅与原发性恶性肿瘤有关,而且还与伴随的非恶性疾病有关。这项研究的目的是调查四种合并症指数[查尔森合并症指数(CCI),Elixhauser方法,美国国立衰老研究所(NIA)和美国国家癌症研究所(NCI)合并症指数以及成人合并症”的预后能力。 Evaluation-27(ACE-27)]用于结直肠癌患者的癌症相关死亡率和全因死亡率。还构建了适用于大肠癌患者的CCI的修改版本。方法:研究人群包括468例2000年1月1日至2010年12月31日期间在社区医院确诊的大肠癌。前瞻性地收集数据,并从患者的临床记录中提取数据。使用Kaplan-Meier方法和多元逻辑回归模型进行生存和死亡风险分析。结果:只有中度或重度肾脏疾病[危险比(HR)2.71,95%置信区间(CI)1.11-6.63]和艾滋病(HR 3.27,95%CI 1.23-8.68)与癌症特异性死亡率独立相关,人口归因风险分别为5.18和4.36%。对于每个指数,最高的合并症负担与较差的总体生存率显着相关(NIA / NCI:HR 2.14,95%CI 1.14-4.01; Elixhauser:HR 1.98,95%CI 1.09-1.42; ACE-27:HR 1.78,95百分比CI 1.07-1.23; CCI:HR 1.68,95%CI 1.05-1.42)和癌症特异性生存率。与其他研究指标相比,CCI的修改版具有更高的预测能力(癌症特异性死亡率HR = 2.37,95%CI 1.37-4.08)。结论:与单一合并症相比,合并症评估工具为大肠癌患者的预后提供了更好的预后预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号